Xiaoming Zou

Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases. We are rapidly advancing our clinical pipelines in an array of trials. Currently, we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH. Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.